Quick Answer
REGENXBIO Inc. reported Net Income Loss of -$193.88 million for the year ending 2025.
- REGENXBIO Inc. showed an increase of +14.6% in Net Income Loss from 2024 to 2025.
- This data is from REGENXBIO Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: $795.0 thousand | Q2 2014: -$672.0 thousand | Q3 2014: -$1.79 million | Q4 2014: -$2.33 million | Q1 2015: -$4.01 million | Q2 2015: -$6.29 million | Q3 2015: -$7.33 million | Q4 2015: -$5.18 million | Q1 2016: -$10.77 million | Q2 2016: -$14.44 million | Q3 2016: -$18.15 million | Q4 2016: -$19.61 million | Q1 2017: -$21.99 million | Q2 2017: -$14.47 million | Q3 2017: -$20.71 million | Q4 2017: -$16.00 million | Q1 2018: $104.24 million | Q2 2018: $10.59 million | Q3 2018: -$19.20 million | Q4 2018: $4.31 million | Q1 2019: -$32.23 million | Q2 2019: -$1.46 million | Q3 2019: -$34.58 million | Q4 2019: -$26.46 million | Q1 2020: -$40.04 million | Q2 2020: -$33.76 million | Q3 2020: $8.79 million | Q4 2020: -$46.24 million | Q1 2021: -$50.14 million | Q2 2021: -$57.64 million | Q3 2021: -$58.41 million | Q1 2022: -$76.72 million | Q2 2022: -$68.18 million | Q3 2022: -$75.48 million | Q1 2023: -$66.68 million | Q2 2023: -$72.06 million | Q3 2023: -$61.87 million | Q1 2024: -$63.33 million | Q2 2024: -$52.99 million | Q3 2024: -$59.60 million | Q1 2025: $6.08 million | Q2 2025: -$70.87 million | Q3 2025: -$61.94 million.
- Over the full 13 years of available data (2013 to 2025), REGENXBIO Inc.'s Net Income Loss has declined by 3,499.0%.
- Historical annual values: Fiscal year 2025: -$193.88 million | Fiscal year 2024: -$227.10 million | Fiscal year 2023: -$263.49 million | Fiscal year 2022: -$280.32 million | Fiscal year 2021: $127.84 million | Fiscal year 2020: -$111.25 million | Fiscal year 2019: -$94.73 million | Fiscal year 2018: $99.94 million | Fiscal year 2017: -$73.17 million | Fiscal year 2016: -$62.97 million | Fiscal year 2015: -$22.81 million | Fiscal year 2014: -$4.00 million | Fiscal year 2013: -$5.39 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: